Minerva Neurosciences, Inc. (NERV) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Minerva Neurosciences reported revenue of $0. Net income was -$293.4M, or -$34.67 per diluted share. Operating activities generated -$13.5M of cash, leaving -$13.5M of free cash flow. At fiscal year end, Minerva Neurosciences held $98.0M in total assets against $233.8M in total liabilities, including $82.3M of cash and equivalents.
Open the full interactive Minerva Neurosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Minerva Neurosciences Key Stats
| Share Price | $2.52 |
|---|---|
| Market Cap | $198.9M |
| 52-Week Range | $2.49 – $8.07 |
| Shares Outstanding | 46.6 million (basic, 2026 Q2) |
Minerva Neurosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $41.2M | $0 | $0 | $0 | $0 | $0 |
| Operating Income | $1.8M | -$45.4M | -$25.2M | -$23.1M | -$21.8M | -$15.1M |
| Pre-Tax Income | $1.9M | -$51.7M | -$32.1M | -$30.0M | $1.4M | -$293.4M |
| Income Tax | — | -$1.8M | — | — | — | — |
| Net Income | $1.9M | -$49.9M | -$32.1M | -$30.0M | $1.4M | -$293.4M |
| Diluted EPS | $0.40 | -$9.36 | -$6.01 | -$4.61 | $0.19 | -$34.67 |
Minerva Neurosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.7M | -$283.7M | -$125.4M | $17.5M |
| Diluted EPS | -$0.36 | -$33.52 | -$2.86 | -$0.14 |
Minerva Neurosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.4M | $60.8M | $36.1M | $40.9M | $21.4M | $82.3M |
| Current Assets | $27.4M | $62.2M | $40.2M | $42.0M | $22.3M | $83.1M |
| Total Assets | $57.6M | $77.1M | $55.1M | $56.9M | $37.1M | $98.0M |
| Current Liabilities | $3.2M | $2.8M | $1.4M | $3.3M | $2.8M | $2.3M |
| Total Liabilities | $5.0M | $69.1M | $75.1M | $85.4M | $62.8M | $233.8M |
| Shareholders' Equity | $52.7M | $8.0M | -$20.0M | -$28.5M | -$25.7M | -$140.7M |
Minerva Neurosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$33.8M | -$24.6M | -$24.6M | -$14.8M | -$19.6M | -$13.5M |
| Cash From Investing | $24.5M | — | -$16,326 | — | $0 | $0 |
| Cash From Financing | $13.2M | $60.0M | -$5 | $19.6M | — | $74.5M |
| Free Cash Flow | -$33.8M | -$24.6M | -$24.6M | -$14.8M | -$19.6M | -$13.5M |
Figures from Minerva Neurosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Minerva Neurosciences financials page for every line item.
Minerva Neurosciences Company Profile
| Ticker | NERV |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Burlington, Massachusetts |
| Incorporated in | Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001598646 |
Frequently Asked Questions
What was Minerva Neurosciences' revenue in fiscal 2025?
Minerva Neurosciences (NERV) reported revenue of $0 for fiscal 2025.
What is Minerva Neurosciences' annual revenue history?
Minerva Neurosciences' annual revenue by fiscal year: 2020: $41.2M; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Minerva Neurosciences' net income in fiscal 2025?
Minerva Neurosciences reported net income of -$293.4M for fiscal 2025.
What was Minerva Neurosciences' earnings per share (EPS) in fiscal 2025?
Minerva Neurosciences' diluted EPS was -$34.67 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Minerva Neurosciences generate in fiscal 2025?
Minerva Neurosciences generated -$13.5M of free cash flow in fiscal 2025.
What was Minerva Neurosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Minerva Neurosciences reported revenue of $0.
How many shares of Minerva Neurosciences are outstanding?
Minerva Neurosciences reported a weighted average of 46.6 million basic shares outstanding in 2026 Q2.
What is Minerva Neurosciences' market cap?
Based on its latest closing price, Minerva Neurosciences (NERV) has a market capitalization of about $198.9M.
When does Minerva Neurosciences' fiscal year end?
Minerva Neurosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Minerva Neurosciences headquartered?
Minerva Neurosciences lists its business address in Burlington, Massachusetts in its SEC filings.